ATE451928T1 - Verfahren zur behandlung von krankheiten mit pflanzenextrakten - Google Patents

Verfahren zur behandlung von krankheiten mit pflanzenextrakten

Info

Publication number
ATE451928T1
ATE451928T1 AT02770452T AT02770452T ATE451928T1 AT E451928 T1 ATE451928 T1 AT E451928T1 AT 02770452 T AT02770452 T AT 02770452T AT 02770452 T AT02770452 T AT 02770452T AT E451928 T1 ATE451928 T1 AT E451928T1
Authority
AT
Austria
Prior art keywords
extracts
methods
administered
diabetics
modulating
Prior art date
Application number
AT02770452T
Other languages
English (en)
Inventor
David Ribnicky
Ilya Raskin
Original Assignee
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers filed Critical Univ Rutgers
Application granted granted Critical
Publication of ATE451928T1 publication Critical patent/ATE451928T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
AT02770452T 2001-08-31 2002-08-30 Verfahren zur behandlung von krankheiten mit pflanzenextrakten ATE451928T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31676001P 2001-08-31 2001-08-31
PCT/US2002/027892 WO2003020026A1 (en) 2001-08-31 2002-08-30 Methods for treating disorders using plant extracts

Publications (1)

Publication Number Publication Date
ATE451928T1 true ATE451928T1 (de) 2010-01-15

Family

ID=23230559

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02770452T ATE451928T1 (de) 2001-08-31 2002-08-30 Verfahren zur behandlung von krankheiten mit pflanzenextrakten

Country Status (8)

Country Link
US (2) US6893627B2 (de)
EP (1) EP1429602B1 (de)
JP (2) JP4744081B2 (de)
AT (1) ATE451928T1 (de)
AU (1) AU2002335689B2 (de)
CA (1) CA2459045A1 (de)
DE (1) DE60234780D1 (de)
WO (1) WO2003020026A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010041187A1 (en) * 1998-10-20 2001-11-15 Carl W Hastings Performance-enhancing dietary supplement
US8703212B2 (en) * 1999-09-03 2014-04-22 Viraj Shah, Varion Limited Base material for pharmaceutical and/or cosmetic cream (herbal composition for itchy or infected skin)
US7713546B1 (en) * 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
KR100645385B1 (ko) * 2005-10-05 2006-11-23 주식회사 안지오랩 비만 억제용 조성물
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2005002602A2 (en) * 2003-06-30 2005-01-13 Nestec S.A. Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance
CA2580733A1 (en) * 2003-09-20 2005-04-07 Glykon Technologies Group, Llc (-)-hydroxycitric acid for delaying gastric emptying
US20080227786A1 (en) * 2004-01-16 2008-09-18 Ferlita Russell R Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor
DE102004036047A1 (de) * 2004-07-24 2006-02-23 Bioghurt Biogarde Gmbh & Co. Kg Physiologisch aktive Zusammensetzung
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
US20100087546A1 (en) * 2005-04-20 2010-04-08 Biogenic Innovations, Llc Use of dimethyl sulfone (msm) to reduce homocysteine levels
BRPI0612413A2 (pt) * 2005-07-05 2011-03-01 Nutricia Nv composição nutricional termicamente tratada, e, uso de uma combinação
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
US9427419B2 (en) 2005-09-12 2016-08-30 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (DMSO)
AU2006291134C1 (en) 2005-09-12 2013-08-15 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
RU2380103C2 (ru) * 2005-09-30 2010-01-27 Моринага Милк Индастри Ко., Лтд. Агент для снижения инсулинорезистентности
JP4165658B2 (ja) 2005-09-30 2008-10-15 森永乳業株式会社 インスリン抵抗性改善剤
US7858599B2 (en) * 2005-12-30 2010-12-28 Hander Robert W Enhancement of urogenital function
US20070224301A1 (en) * 2006-03-21 2007-09-27 Ribnicky David M Compounds from an extract of Artemisia and methods for treating disorders
US20070264360A1 (en) * 2006-05-12 2007-11-15 Feldman Spencer B Gall bladder and liver cleansing suppository
WO2007137128A1 (en) 2006-05-19 2007-11-29 Mary Kay Inc. Glyceryl and glycol acid compounds
US20090061031A1 (en) * 2006-07-07 2009-03-05 Sylvia Lee-Huang Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus
UA100673C2 (uk) 2006-07-21 2013-01-25 Ксилеко, Инк. Спосіб переробки целюлозної або лігноцелюлозної біомаси (варіанти)
ES2712706T3 (es) * 2006-10-05 2019-05-14 Dsm Ip Assets Bv Uso de hidroxitirosol para reducir la cantidad de ácido láctico en plasma
CN101102783B (zh) * 2006-12-13 2010-11-17 北京绿色金可生物技术股份有限公司 黑大豆皮提取物及其提取方法和应用
IL181404A0 (en) * 2007-02-18 2007-07-04 R A M Biotechnological Res Ltd Herbal compositions comprising plant material of artemisia herba-alba (asso) asteraceae and/or extracts thereof
US8187643B2 (en) * 2007-03-28 2012-05-29 Greg Steininger, legal representative Shampoo formulation for treatment of hair loss and method of use
US20080311230A1 (en) * 2007-06-17 2008-12-18 Omer Harun A Preparation of Artemisia to treat human cancer, autoimmune disease, IgA-Nephropathy, and to counteract weight loss in cancer patients
IL184312A0 (en) * 2007-06-28 2008-01-20 Ascarit Ltd Herbal compositions for the treatment of diabetes and/or conditions associated therewith
US20090263505A1 (en) * 2008-04-21 2009-10-22 George Roderick Hammons Dietary therapeutic compositions for ameliorating disease symptoms and conditions associated with diabetes
EP2130443A1 (de) * 2008-06-06 2009-12-09 Finzelberg GmbH & Co. KG Wasserlösliche Extrakte von Artemisia dracunculus (Tarragon) zur Verbesserung des Glukosestoffwechsels
US20110123654A1 (en) * 2008-06-06 2011-05-26 Ralf Jaeger Synergistic enhancement of cellular ergogenic nutrient uptake, like creatine or carnitine, with tarragon
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
CN101548982B (zh) * 2009-05-12 2012-02-01 中国人民解放军第二军医大学 一种二氢黄酮类化合物在制备防治糖尿病药物中的应用
CA2779111C (en) 2009-10-30 2019-08-13 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis
WO2011075741A1 (en) * 2009-12-18 2011-06-23 Metabolic Technologies, Inc. Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)
MX2013004364A (es) 2010-10-19 2013-07-02 Elcelyx Therapeutics Inc Terapias a base de ligando del receptor quimiosensorial.
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
TWI495464B (zh) * 2013-02-08 2015-08-11 Univ Nat Taiwan 苦味化合物於活化ｇｌｐ－１分泌之用途
CA2905857A1 (en) * 2013-03-12 2014-10-09 HMI Medical Innovations, LLC Plant extracts with anti-diabetic and other useful activities
CA2905121C (en) 2013-03-12 2021-10-26 Mary Kay Inc. Preservative system
EP3140316A1 (de) 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Zusammensetzungen und verfahren im zusammenhang mit ionischen salzen von peptiden
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
DK3157936T3 (en) 2014-06-18 2019-02-04 Thetis Pharmaceuticals Llc MINERAL AMINO ACID ACID COMPLEXES OF ACTIVE SUBSTANCES
EP3209300B1 (de) 2014-10-21 2022-03-16 Alpinia Laudanum Institute Of Phytopharmaceutical Sciences AG Extrakt aus einer pflanze der gattung boswellia und zugehörige produkte und verwendungen
EP3454907B1 (de) 2016-06-03 2020-07-22 Thetis Pharmaceuticals LLC Zusammensetzungen und verfahren in zusammenhang mit salzen von specialised pro-resolving mediatoren von entzündung
CA3063110A1 (en) * 2017-05-12 2018-11-15 Housey Pharmaceutical Research Laboratories, L.L.C. Plant extracts with anti-diabetic and other useful activities
CN112336847B (zh) * 2021-01-11 2021-07-13 中城环建科技股份有限公司 益生菌组合物在制备药物中的用途
CN112931120B (zh) * 2021-01-29 2023-01-24 中国科学院地理科学与资源研究所 一种在盐碱地种植胡芦巴的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534317A (en) * 1984-08-30 1985-08-13 Cape Cod Research Procedures for monitoring fish food consumption
JPH0356585A (ja) * 1989-07-26 1991-03-12 Shokuhin Sangyo Hai Separeeshiyon Syst Gijutsu Kenkyu Kumiai 抗酸化剤
JP3536111B2 (ja) * 1992-06-29 2004-06-07 株式会社ナリス化粧品 ムコ多糖類断片化抑制剤および化粧料
GB9606579D0 (en) 1996-03-28 1996-06-05 Phytotech Ltd Pharmaceutical composition and methods for the manufacture thereof
JPH1036280A (ja) * 1996-07-18 1998-02-10 Pola Chem Ind Inc ヒドロキシラジカル消去剤
JPH1036282A (ja) * 1996-07-18 1998-02-10 Pola Chem Ind Inc ムコ多糖類切断抑制剤
JPH1077211A (ja) * 1996-09-05 1998-03-24 Pola Chem Ind Inc メークアップ化粧料
JP4127875B2 (ja) * 1997-06-11 2008-07-30 株式会社ロッテ 抗ヘリコバクター・ピロリ剤
JP3978517B2 (ja) * 1997-07-25 2007-09-19 株式会社ロッテ 抗レジオネラ属菌組成物
JPH11318445A (ja) * 1998-05-14 1999-11-24 Aomori Prefecture ノイラミニダーゼ阻害物質製造法
KR20000019716A (ko) * 1998-09-15 2000-04-15 박호군 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
IN187160B (de) * 1998-09-26 2002-02-16 Kijang Medical Co

Also Published As

Publication number Publication date
US6893627B2 (en) 2005-05-17
US20050069598A1 (en) 2005-03-31
EP1429602A1 (de) 2004-06-23
WO2003020026A1 (en) 2003-03-13
JP2005505544A (ja) 2005-02-24
JP2010018637A (ja) 2010-01-28
DE60234780D1 (de) 2010-01-28
EP1429602B1 (de) 2009-12-16
AU2002335689B2 (en) 2008-08-07
US20030072822A1 (en) 2003-04-17
EP1429602A4 (de) 2005-12-21
CA2459045A1 (en) 2003-03-13
JP4744081B2 (ja) 2011-08-10

Similar Documents

Publication Publication Date Title
ATE451928T1 (de) Verfahren zur behandlung von krankheiten mit pflanzenextrakten
DE602005020269D1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
DE69132098D1 (de) Verfahren zur amplifikation von nukleinsäuren
ATE411399T1 (de) Behandlung der huntington's krankheit mit epa
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE395052T1 (de) Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
ATE30326T1 (de) Cyclische pentapeptide mit somatostatin antagonistischer wirksamkeit und verfahren zur behandlung von saeugetieren damit.
ATE425151T1 (de) Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung von mit dem insulinresistenzsyndrom assoziierten erkrankungen eignen
ATE373014T1 (de) Einen nanofiltrationsschritt umfassendes verfahren zur aufreinigung von albumin, lösung und zusammensetzung zur therapeutischen anwendung,die dieses enthalten
DE69228949D1 (de) Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
PT87523A (pt) Mischkristalle aus insulin und insulinderivaten verfahren zur herstellung dieser mischkristalle diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
ATE545658T1 (de) Verfahren zur behandlung von synovialsarkom
DK0769915T3 (da) Anvendelse af en fraktion indeholdende organiske syrer og fraktion indeholdende syre
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DK577181A (da) Polypeptidfraktioner fra muslinger
DE3686108D1 (de) Verwendung von p-chlorophenoxyazetat von n,n-dimethylbiguanid zur behandlung von neuropathien und nervendegeneration.
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE59206036D1 (de) Piperidylmethyl substituierte Chromanderivate als Wirkstoffe zur Behandlung von Erkrankungen des Zentralnervensystems
ATE66340T1 (de) Verfahren zur foerderung von wachstum und gesundheit von nutzpflanzen.
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
EA200500765A1 (ru) Применение докозагексановой кислоты в качестве активного вещества для лечения липодистрофии
DE68914660D1 (de) Verfahren zur Herstellung von den Safranblütennarben ähnlichem Gewebe sowie Verfahren zur Herstellung von nützlichen Stoffen aus safranblütennarbenähnlichem Gewebe.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties